ProMIS Neurosciences IPO year
What is the IPO year of ProMIS Neurosciences?
The IPO year of ProMIS Neurosciences, Inc. is 2007
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on TSX compared to ProMIS Neurosciences
What does ProMIS Neurosciences do?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Companies with ipo year similar to ProMIS Neurosciences
- G3 Exploration has IPO year of 2006
- Evolis SA has IPO year of 2006
- Unity Infraprojects has IPO year of 2006
- News Invest has IPO year of 2006
- AuStar Gold has IPO year of 2006
- Sky and Space Global has IPO year of 2006
- ProMIS Neurosciences has IPO year of 2007
- Manas Resources has IPO year of 2008
- Mastech Digital Inc has IPO year of 2008
- MYR Inc has IPO year of 2008
- Dana Inc has IPO year of 2008
- American Water Works Co has IPO year of 2008
- Chromadex Corp has IPO year of 2008